调强放疗联合厄洛替尼治疗晚期食管癌的疗效观察  

Intensity-modulated radiotherapy combined with erlotinib advanced esophageal cancer: observation of effects

作　　者：周宓[1] 孙婷婷[1] 杨金霞[1] 王宗站[1] 邢晓波[1] 

机构地区：[1]青岛市肿瘤医院放疗科,山东青岛266042

出　　处：《现代医学》2015年第4期438-441,共4页Modern Medical Journal

摘　　要：目的:探究调强放疗(IMRT)联合厄洛替尼治疗晚期食管癌的疗效和安全性,为临床晚期食管癌的治疗提供参考。方法:选择晚期食管癌患者87例作为研究对象,对照组41例采用单纯IMRT,试验组46例采用IMRT配合厄洛替尼治疗,观察分析两组患者的临床疗效和不良反应发生情况,并随访第1、2年的生存状况。结果:试验组患者有效率(86.96%)明显高于对照组(43.90%)(χ2=18.083,P<0.05),放射性食管炎、口腔黏膜炎、放射性肺炎、骨髓抑制、消化道反应等不良反应发生率两组间差异均有统计学意义(P<0.05),虽然第1、2年的生存率对照组(68.29%、48.78%)略高于试验组(65.22%、47.83%),但两组间生存状况的差异无统计学意义(χ2=0.092、χ2=0.008,P=0.761、P=0.929)。结论:调强放疗联合厄洛替尼对晚期食管癌治疗效果显著,且并发症少,临床可以作为晚期食管癌治疗的一种参考方法。Objective： To explore the efficacy and safety of intensity-modulated radiotherapy （IMRT） combined wlth erlotinib in the treatment of advanced esophageal esophageal cancer. Methods： 87 patients clinically cancer and to provide guidance for the treatment of advanced diagnosed as advanced esophageal carcinoma in our hospital were enrolled from march,2013 to may,2014. 41 cases in control group （47. 13% ） received simple IMRT treatment, 46 patients （52. 87% ） in experimental group had IMRT combined with erlotinib. At the end of treatment, clinical curative effect and adverse reaction were observed and analyzed between the two groups. Also the patients were followed up for 2 years for their survival status. Results： After the treatment, the patients in the control group had an effective rate of 43.90% ,the experimental group 86.96% ; there was a significant difference between two groups（χ^2= 18. 083 ,P 〈0.05 ）. Adverse reactions were radioactive esophagitis, oral cavity mucositis, radiation pneumonitis, bone marrow transplantation, digestive tract reaction; there were statistical differences between the two groups （P 〈 0.05 ）. 2 years of follow- up showed no difference of living conditions between the two groups（χ^2=0.092,0. 008 ;P = 0. 761, 0. 929 ） , although the 1 and 2 year survival rate（68.29% ,48.78% ） was greater than that of the experimental group（65.22% ,47.83% ）. Conclusion： The effect of IMRT combined with erlotinib for the treatment of advanced esophageal carcinoma is significant, and has fewer complications, which can be a reference method as the treatment for advanced esophageal carcinoma.

关 键 词：调强放疗 厄洛替尼 食管癌 临床疗效 不良反应 

分 类 号：R735.1[医药卫生—肿瘤]